TABLE 2

Plasma PLTP mass and activity and apoE and apoAI levels before and after treatment

VariableBaselineWeek 30% change
PLTP mass (mg/l)
    Placebo8.88 ± 2.578.83 ± 2.70−0.6
    10 mg atorvastatin9.00 ± 3.289.26 ± 3.152.8*
    80 mg atorvastatin8.63 ± 3.119.63 ± 3.0911.6
PLTP activity (%)
    Placebo106.7 ± 18.0107.3 ± 18.80.9
    10 mg atorvastatin107.8 ± 18.399.7 ± 16.1−8.3
    80 mg atorvastatin108.8 ± 21.896.8 ± 18.6−12.1
ApoE (mg/100 ml)
    Placebo4.46 ± 0.804.52 ± 1.120.9
    10 mg atorvastatin4.34 ± 1.023.15 ± 0.83−28
    80 mg atorvastatin4.68 ± 1.172.99 ± 1.06−36
ApoAI (mg/100 ml)
    Placebo141 ± 19137 ± 18−2.8
    10 mg atorvastatin139 ± 20138 ± 20−0.71
    80 mg atorvastatin139 ± 21134 ± 20−3.6
  • Data are the means ± SD, and PLTP activity is % of reference plasma. Placebo: n = 71; A10: n = 72; A80: n = 72. Test was for difference among the three groups, adjusted for baseline value.

  • *

    * P < 0.003 A10 vs. A80;

  • P < 0.001 vs. placebo;

  • P < 0.01 vs. placebo.